 |
| |
| Agenda |
| |
(As of September 11, 2006-subject to change)
October 4, 2006
| 7:30 –
8:30 a.m. |
Registration |
| |
Predictors of
Type 2 Diabetes
Moderator: Myrlene Staten, M.D., NIDDK |
| 8:30 – 8:45
a.m. |
Welcome and Introduction to the Meeting
Judith Fradkin, M.D., NIDDK |
| 8:45 – 9:30
a.m. |
Current Status of Predictive Models—Known
Key Variables
Mike Stern, M.D., University of Texas at San Antonio |
| 9:30 –
10:15 a.m. |
Potential New Predictors—Leveraging New Scientific Insights
Jorge Plutzky, M.D., Brigham & Women’s Hospital |
| 10:15 –
10:45 a.m. |
BREAK |
| 10:45 –
11:30 a.m. |
Inhibitors and Motivators for Prevention of Diabetes: Understanding Them Through Research
K.M. Venkat Narayan, M.D., M.P.H., M.B.A., Emory University |
| 11:30 –
12:00 noon |
Discussion |
| 12:00 –
1:30 p.m. |
LUNCH |
| |
Common Etiological Pathways for Syndromes Associated with
Obesity and Insulin Resistance
Moderator: Phil Smith, M.D., NIDDK |
| 1:30 – 2:15
p.m. |
Overview of the Currently Proposed
Etiological Pathways and How They Might Intersect and How
Nuclear Receptors Fit into the Picture
Mitch Lazar, M.D., Ph.D., University of Pennsylvania |
| 2:15 – 2:45
p.m. |
Macrophages, Inflammation and Insulin
Resistance
Anthony Ferrante, M.D., Ph.D., Columbia University |
| 2:45 – 3:15
p.m. |
Inflammation, NF-κβ and Insulin
Resistance
Steven Shoelson, M.D., Ph.D., Joslin Diabetes Center |
| 3:15 –
3:45 p.m. |
BREAK |
| 3:45 – 4:15
p.m. |
Inflammation, Insulin Resistance and Atherothrombotic Vascular Disease
John Yudkin, M.D., Ph.D., London University |
| 4:15 – 4:45
p.m. |
Discussion |
| 4:45 – 5:00
p.m. |
Regulatory Perspectives on Guidances
FDA |
| 5:00 – 5:15
p.m. |
Discussion |
| 5:15
p.m. |
Adjourn |
| |
|
October 5, 2006
| 7:30 –
8:30 a.m. |
Registration |
| |
|
Prevention of
Type 2 Diabetes
Moderator: Robert Misbin, M.D., FDA |
| 8:30 – 9:15
a.m. |
Overview of Currently Available Clinical Data
Fred Brancati, M.D., M.S.H., John Hopkins University
Point—Counter Point
Are the available data sufficient to support an indication
for treatment to prevent Type 2 Diabetes for currently
studied drugs? |
| 9:15 – 9:45
a.m. |
Yes, They Are Sufficient
David Nathan, M.D., Massachusetts General |
| 9:45 –
10:15 a.m. |
No, They are not Sufficient, More Data is Needed
Elizabeth Barrett-Connor, M.D., University of California at
San Diego |
| 10:15 –
10:30 a.m. |
BREAK |
| 10:30 –
11:30 a.m. |
Panel Discussion of the Strengths and
Weaknesses of the Above Positions, Given the Data Presented
and Discussed. What Other Data Needs to be Generated, if
any? |
| 11:30 –
12:00 noon |
Summarization of Main Points
Robert Eckel, M.D., University of Colorado |
| |
|
Panelists (in
addition to the speakers):
Robert Eckel, M.D., University of Colorado
William Knowler, M.D., NIDDK, Phoenix |
| |
|
Back to Top
|
|
